Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

MilliporeSigma adding 160 jobs in Covid-fueled expansion

MilliporeSigma is in the process of adding 160 jobs at its Jaffrey facility as the global life sciences company ramps up production of components used to develop potential Covid-19 treatments and vaccines. The Jaffrey facility primarily makes filtration devices that are used to produce biopharmaceuticals, such as immunotherapies for cancer treatment. These sorts of products are also part of the standard process for making vaccines, said David Poggi, the plant’s director of operations.. The company’s customers are mainly pharmaceutical corporations, and MiliporeSigma is currently supplying more than 45 companies that are working to develop a Covid-19 vaccine.